| 利用者成果(英) |
|
21677
Kim S, Lee Y, Song BR, Sim H, Kang EH, Hwang M, Yu N, Hong S, Park C, Ahn BC, Lim EJ, Hwang KH, Park SY, Choi JH, Lee GK, Han JY.
Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy.
Cancers (Basel)
2024
16(4)
PubMed ID: 38398169
DOI: 10.3390/cancers16040778
|
|
21706
Ando S, Tanaka K, Matsumoto M, Oyama Y, Tomabechi Y, Yamagata A, Shirouzu M, Nakagawa R, Okimoto N, Taiji M, Sato K, Ohama T.
The luciferase-based in vivo protein-protein interaction assay revealed that CHK1 promotes PP2A and PME-1 interaction.
J Biol Chem
2024
107277
PubMed ID: 38588804
DOI: 10.1016/j.jbc.2024.107277
|
|
21743
Zha L, Matsu-Ura T, Sluka JP, Murakawa T, Tsuta K.
Morphological basis of the lung adenocarcinoma subtypes.
iScience
2024
27(5):109742
PubMed ID: 38706836
DOI: 10.1016/j.isci.2024.109742
|
|
21749
Kohsaka S, Yagishita S, Shirai Y, Matsuno Y, Ueno T, Kojima S, Ikeuchi H, Ikegami M, Kitada R, Yoshioka KI, Toshimitsu K, Tabata K, Yokoi A, Doi T, Yamamoto N, Owa T, Hamada A, Mano H.
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.
NPJ Precis Oncol
2024
8(1):117
PubMed ID: 38789724
DOI: 10.1038/s41698-024-00610-0
|
|
21840
Muneer G, Chen CS, Lee TT, Chen BY, Chen YJ.
A Rapid One-Pot Workflow for Sensitive Microscale Phosphoproteomics.
J Proteome Res
2024
PubMed ID: 39038167
DOI: 10.1021/acs.jproteome.3c00862
|
|
21865
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, Ishida M, Kawachi H, Nakamura R, Nishioka N, Morimoto K, Iwasaku M, Horinaka M, Sakai T, Tokuda S, Takayama K.
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells
Cancer Sci
2024
Jul 22
PubMed ID: 39039802
DOI: 10.1111/cas.16292
|
|
21873
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K.
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Cancer Lett
2024
598:217124
PubMed ID: 39059573
DOI: 10.1016/j.canlet.2024.217124
|
|
22056
Geng L, Matsumoto M, Yao F, Umino M, Kamiya M, Mukai H, Kawakami S.
Microfluidic post-insertion of polyethylene glycol lipids and KK or RGD high functionality and quality lipids in milk-derived extracellular vesicles.
Eur J Pharm Sci
2024
106929
PubMed ID: 39389168
DOI: 10.1016/j.ejps.2024.106929
|
|
22127
Kim Y, Oh HC, Lee S, Kim HH.
Saturation profiling of drug-resistant genetic variants using prime editing.
Nat Biotechnol
2024
PubMed ID: 39533107
DOI: 10.1038/s41587-024-02465-z
|
|
17817
Ohkawa Y, Kitano M, Maeda K, Nakano M, Kanto N, Kizuka Y, Seike M, Azuma A, Yamaguchi Y, Ookawara T, Miyoshi E, Taniguchi N.
Core Fucosylation Is Required for the Secretion of and the Enzymatic Activity of SOD3 in Nonsmall-Cell Lung Cancer Cells
Antioxid Redox Signal
2023
Mar 6
PubMed ID: 36606688
DOI: 10.1089/ars.2022.0010
|
|
19676
Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR.
Microfluidics-free single-cell genomics with templated emulsification
Nat Biotechnol
2023
41(11):1557-1566
PubMed ID: 36879006
DOI: 10.1038/s41587-023-01685-z
|
|
19697
Nakamura R, Fujii H, Yamada T, Matsui Y, Yaoi T, Honda M, Tanaka N, Miyagawa-Hayashino A, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Konishi E, Itoh K, Takayama K.
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
JTO Clin Res Rep
2023
4(6):100525
PubMed ID: 37426308
DOI: 10.1016/j.jtocrr.2023.100525
|
|
19731
Kosai K, Masuda T, Kitagawa A, Tobo T, Ono Y, Ando Y, Takahashi J, Haratake N, Kohno M, Takenaka T, Yoshizumi T, Mimori K.
Transducin Beta-Like 2 is a Potential Driver Gene that Adapts to Endoplasmic Reticulum Stress to Promote Tumor Growth of Lung Adenocarcinoma
Ann Surg Oncol
2023
30(12):7538-7548
PubMed ID: 37477745
DOI: 10.1245/s10434-023-13864-y
|
|
19976
Gunasekaran P, Hwang YS, Lee GH, Park J, Kim JG, La YK, Park NY, Kothandaraman R, Yim MS, Choi J, Kim HN, Park IY, Lee SJ, Kim MH, Cha-Molstad H, Shin SY, Ryu EK, Bang JK.
Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer
J Med Chem
2023
Dec 17
PubMed ID: 38105611
DOI: 10.1021/acs.jmedchem.3c01493
|
|
20946
Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S.
MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
Cancer Med
2023
12(5):5809-5820
PubMed ID: 36416133
DOI: 10.1002/cam4.5342
|
|
21119
Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Okada M, Hamada H, Hattori N.
Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.
Cancers (Basel)
2023
15(4)
PubMed ID: 36831438
DOI: 10.3390/cancers15041092
|
|
21131
Konishi H, Haga Y, Lin Y, Tsujino H, Higashisaka K, Tsutsumi Y.
Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.
Biochem Biophys Res Commun
2023
641:116-122
PubMed ID: 36527745
DOI: 10.1016/j.bbrc.2022.12.029
|
|
21136
Sumimoto H, Takano A, Igarashi T, Hanaoka J, Teramoto K, Daigo Y.
Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma.
Sci Rep
2023
13(1):5087
PubMed ID: 36991099
DOI: 10.1038/s41598-023-32177-4
|
|
21224
Kim M, Kim S, Yim J, Keam B, Kim TM, Jeon YK, Kim DW, Heo DS.
Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Cancer Res Treat
2023
PubMed ID: 37218137
DOI: 10.4143/crt.2023.311
|
|
17574
Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.
Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells
Cancer Sci
2022
113(7):2323-2335
PubMed ID: 35363931
DOI: 10.1111/cas.15354
|
|
20516
Fan D, Yang Y, Zhang W.
A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
BMC Pulm Med
2022
22(1):27
PubMed ID: 34996416
DOI: 10.1186/s12890-021-01731-z
|
|
20523
Gebreyesus ST, Siyal AA, Kitata RB, Chen ES, Enkhbayar B, Angata T, Lin KI, Chen YJ, Tu HL.
Streamlined single-cell proteomics by an integrated microfluidic chip and data-independent acquisition mass spectrometry.
Nat Commun
2022
13(1):37
PubMed ID: 35013269
DOI: 10.1038/s41467-021-27778-4
|
|
20529
Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K.
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Cancer Med
2022
11(4):944-955
PubMed ID: 35029047
DOI: 10.1002/cam4.4504
|
|
20595
Matsushige T, Sakabe T, Umekita Y.
Investigation of the Subcellular Localization-Dependent Anti- or Pro-Tumor Functions of Maspin in Human Lung Adenocarcinoma Cell Line.
Yonago Acta Med
2022
65(1):44-52
PubMed ID: 35221759
DOI: 10.33160/yam.2022.02.006
|
|
16503
Tsuchiya K, Yoshimura K, Iwashita Y, Inoue Y, Ohta T, Watanabe H, Yamada H, Kawase A, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H.
m 6 A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer
Cancer Gene Ther
2022
Mar 22
PubMed ID: 35318440
DOI: 10.1038/s41417-022-00451-8
|
|
16726
Grinkevitch V, Wappett M, Crawford N, Price S, Lees A, McCann C, McAllister K, Prehn J, Young J, Bateson J, Gallagher L, Michaut M, Iyer V, Chatzipli A, Barthorpe S, Ciznadija D, Sloma I, Wesa A, Tice DA, Wessels L, Garnett M, Longley DB, McDermott U, McDade SS.
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Mol Cancer Ther
2022
21(4):594-606
PubMed ID: 35086954
DOI: 10.1158/1535-7163.MCT-21-0532
|
|
16854
Masaki Takahashi, Yoshifumi Hashimoto, Yoshikazu Nakamura
Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model
Molecular Therapy - Nucleic Acids
2022
29:969-978
PubMed ID: 36189081
DOI: 10.1016/j.omtn.2022.06.001
|
|
20821
Li C, Zheng H, Xiong J, Huang Y, Li H, Jin H, Ai S, Wang Y, Su T, Sun G, Xiao X, Fu T, Wang Y, Gao X, Liang P.
miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8.
Cell Death Dis
2022
13(8):699
PubMed ID: 35961957
DOI: 10.1038/s41419-022-05062-7
|
|
20848
Satoh K, Sakai S, Nishizuka M.
Knockdown of RhoQ, a member of Rho GTPase, accelerates TGF-β-induced EMT in human lung adenocarcinoma.
Biochem Biophys Rep
2022
32:101346
PubMed ID: 36120491
DOI: 10.1016/j.bbrep.2022.101346
|
|
20859
Onishi T, Takashima T, Kurashige M, Ohshima K, Morii E.
Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma.
Pathol Res Pract
2022
238:154071
PubMed ID: 35985089
DOI: 10.1016/j.prp.2022.154071
|
|
20935
Deng H, Lei Q, Wang C, Wang Z, Chen H, Wang G, Yang N, Huang D, Yu Q, Yao M, Xiao X, Zhu G, Cheng C, Li Y, Li F, Tian P, Li W.
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.
Nat Commun
2022
13(1):6944
PubMed ID: 36376325
DOI: 10.1038/s41467-022-34627-5
|
|
21853
Yuki Oka, Larina Tzu-Wei Shen, Tomoko Mori, Takumi Iwamura, Philippe Leproux, Satoshi Matsusaka, Hideaki Kano
Label-free visualization of cellular response to molecularly targeted agents using multiplex coherent anti-Stokes Raman scattering and third harmonic generation microscopy
Applied Physics Express
2022
15:102001
DOI: 10.35848/1882-0786/ac8d47
|
|
20104
Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y.
Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer.
Cancer Med
2021
PubMed ID: 33826244
DOI: 10.1002/cam4.3852
|
|
14291
Isomura H, Taguchi A, Kajino T, Asai N, Nakatochi M, Kato S, Suzuki K, Yanagisawa K, Suzuki M, Fujishita T, Yamaguchi T, Takahashi M, Takahashi T.
Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator
Cancer Sci
2021
112(4):1614-1623
PubMed ID: 33506575
DOI: 10.1111/cas.14825
|
|
14368
Khaledian B, Taguchi A, Shin-Ya K, Kondo-Ida L, Kagaya N, Suzuki M, Kajino T, Yamaguchi T, Shimada Y, Takahashi T.
Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma
Cancer Sci
2021
112(3):1225-1234
PubMed ID: 33370472
DOI: 10.1111/cas.14786
|
|
20304
Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K.
Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.
Lung Cancer
2021
158:115-125
PubMed ID: 34157583
DOI: 10.1016/j.lungcan.2021.06.011
|
|
20365
He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H, Xu R.
Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer.
Am J Cancer Res
2021
11(9):4329-4346
PubMed ID: 34659890
|
|
15836
Nanamiya R, Saito-Koyama R, Miki Y, Inoue C, Asavasupreechar T, Abe J, Sato I, Sasano H.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer
Int J Mol Sci
2021
22(16):8522
PubMed ID: 34445227
DOI: 10.3390/ijms22168522
|
|
15839
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.
dentification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Nat Commun
2021
12(1):3697
PubMed ID: 34140482
DOI: 10.1038/s41467-021-23912-4
|
|
15840
Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S.
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer
Cancer Sci
2021
112(9):3784-3795
PubMed ID: 34145930
DOI: 10.1111/cas.15035
|
|
15846
Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H.
Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
Cancer Med
2021
10(2):718-727
PubMed ID: 33305905
DOI: 10.1002/cam4.3639
|
|
15883
Xue L, Gao X, Zhang H, Tang J, Wang Q, Li F, Li X, Yu X, Lu Z, Huang Y, Tang R, Yang W.
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
BMC Cancer
2021
21(1):1134
PubMed ID: 34686154
DOI: 10.1186/s12885-021-08859-5
|
|
16219
Jeongmin Hong, Aya Shiba‐Ishii, Yunjung Kim, Masayuki Noguchi, Noriaki Sakamoto
Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma
Cancer Sci
2021
112(12):5114-5126
PubMed ID: 34628698
DOI: 10.1111/cas.15160
|
|
16281
Nachankar A, Oike T, Hanaoka H, Kanai A, Sato H, Yoshida Y, Obinata H, Sakai M, Osu N, Hirota Y, Takahashi A, Shibata A, Ohno T.
64 Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
Cancers (Basel)
2021
13(24):6159
PubMed ID: 34944777
DOI: 10.3390/cancers13246159
|
|
20624
Nozaki M, Nishizuka M.
Repression of RhoJ expression promotes TGF-β-mediated EMT in human non-small-cell lung cancer A549cells.
Biochem Biophys Res Commun
2021
566:94-100
PubMed ID: 34119829
DOI: 10.1016/j.bbrc.2021.06.004
|
|
16516
Tsuchiya K, Yoshimura K, Inoue Y, Iwashita Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H.
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer
Oncoimmunology
2021
10(1):1962656
PubMed ID: 34408926
DOI: 10.1080/2162402X.2021.1962656
|
|
18105
Liu J, Han X, Chen L, Han D, Mu X, Hu X, Wu H, Wu H, Liu W, Zhao Y.
TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma
Aging (Albany NY)
2020
12(20):20308-20331
PubMed ID: 33091876
DOI: 10.18632/aging.103804
|
|
7054
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S.
Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
J Thorac Oncol
2020
15(5):752-765
PubMed ID: 31972351
DOI: 10.1016/j.jtho.2020.01.001
|
|
11955
Ren T, Fan XX, Wang MF, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW, Tang YJ, Leung EL.
miR‑20b promotes growth of non‑small cell lung cancer through a positive feedback loop of the Wnt/β‑catenin signaling pathway.
Int. J. Oncol.
2020
PubMed ID: 31894264
DOI: 10.3892/ijo.2019.4940
|
|
12050
Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, Shimizu K, Shirabe K, Kuwano H.
Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells.
Surg. Today
2020
PubMed ID: 32052182
DOI: 10.1007/s00595-020-01976-x
|
|
12085
Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y.
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Sci Rep
2020
PubMed ID: 32179851
DOI: 10.1038/s41598-020-61727-3
|
|
12089
Tanaka H, Hino H, Moriya S, Kazama H, Miyazaki M, Takano N, Hiramoto M, Tsukahara K, Miyazawa K.
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin.
Biochem Biophys Rep
2020
PubMed ID: 32195376
DOI: 10.1016/j.bbrep.2020.100750
|
|
13153
Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C.
Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.
Biomedicines
2020
PubMed ID: 32764319
DOI: 10.3390/biomedicines8080273
|
|
13224
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Nat Commun
2020
PubMed ID: 32929081
DOI: 10.1038/s41467-020-18442-4
|
|
13283
Arai S, Takeuchi S, Fukuda K, Tanimoto A, Nishiyama A, Konishi H, Takagi A, Takahashi H, Ong ST, Yano S.
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
J Med Invest
2020
PubMed ID: 33148913
DOI: 10.2152/jmi.67.343
|
|
13543
Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H.
Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells
Front Immunol
2020
11:1405
PubMed ID: 32793196
DOI: 10.3389/fimmu.2020.01405
|
|
13922
Kim H, Ishibashi K, Iijima M, Kuroda S, Nakamura C.
Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy
Sensors (Basel)
2020
20(19):5723
PubMed ID: 33050090
DOI: 10.3390/s20195723
|
|
14793
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Clin Cancer Res
2020
26(9):2244-2256
PubMed ID: 31953310
DOI: 10.1158/1078-0432.CCR-19-2321
|
|
14832
Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.
Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines
Arch Virol
2020
165(1):207-214
PubMed ID: 31776677
DOI: 10.1007/s00705-019-04474-9
|
|
14834
Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H.
11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma
Br J Cancer
2020
123(1):61-71
PubMed ID: 32336752
DOI: 10.1038/s41416-020-0837-3
|
|
17870
Yamaguchi T, Hayashi M, Ida L, Yamamoto M, Lu C, Kajino T, Cheng J, Nakatochi M, Isomura H, Yamazaki M, Suzuki M, Fujimoto T, Takahashi T.
ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma
Oncogene
2019
38(26):5142-5157
PubMed ID: 30894682
DOI: 10.1038/s41388-019-0785-7
|
|
11336
Kosibaty Z, Murata Y, Minami Y, Dai T, Kano J, Matsuoka R, Nakano N, Noguchi M.
Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression.
Lab. Invest.
2019
PubMed ID: 30542068
DOI: 10.1038/s41374-018-0142-4
|
|
11372
Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.
Cell Rep
2019
PubMed ID: 30625329
DOI: 10.1016/j.celrep.2018.12.043
|
|
11384
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Nat Commun
2019
PubMed ID: 30651547
DOI: 10.1038/s41467-018-08074-0
|
|
11421
Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
J. Cell. Mol. Med.
2019
PubMed ID: 30734495
DOI: 10.1111/jcmm.14205
|
|
11453
Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J, Sato I, Okada Y, Sasano H.
The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma.
Oncotarget
2019
PubMed ID: 30800222
DOI: 10.18632/oncotarget.26637
|
|
11461
Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.
Cancers (Basel)
2019
PubMed ID: 30818860
DOI: 10.3390/cancers11030282
|
|
4870
Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S.
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Mol Cancer Res
2019
17(11):2233-2243
PubMed ID: 31467113
DOI: 10.1158/1541-7786.MCR-19-0419
|
|
11746
Mizutani K, Guo X, Shioya A, Zhang J, Zheng J, Kurose N, Ishibashi H, Motono N, Uramoto H, Yamada S.
The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Int J Med Sci
2019
PubMed ID: 31588184
DOI: 10.7150/ijms.36071
|
|
11808
Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M.
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.
Anticancer Res.
2019
PubMed ID: 31519584
DOI: 10.21873/anticanres.13667
|
|
11848
Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M.
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.
Cancers (Basel)
2019
PubMed ID: 31614999
DOI: 10.3390/cancers11101550
|
|
6892
Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M.
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Oncol Rep
2019
42(2):839-848
PubMed ID: 31173242
DOI: 10.3892/or.2019.7185
|
|
12553
Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y.
EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis
Int J Oncol
2019
54(1):370-380
PubMed ID: 30431083
DOI: 10.3892/ijo.2018.4626
|
|
14275
Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Clin Cancer Res
2019
25(4):1248-1260
PubMed ID: 30352902
DOI: 10.1158/1078-0432.CCR-18-1640
|
|
14474
Mizuta S, Tagod MSO, Iwasaki M, Nakamura Y, Senju H, Mukae H, Morita CT, Tanaka Y.
Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates
ChemMedChem
2019
14(4):462-468
PubMed ID: 30637982
DOI: 10.1002/cmdc.201800764
|
|
14810
Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Mol Cancer Res
2019
17(2):499-507
PubMed ID: 30463991
DOI: 10.1158/1541-7786.MCR-18-0628
|
|
10633
Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T.
Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens.
Oncol Lett
2018
15:1469-1474
PubMed ID: 29399190
DOI: 10.3892/ol.2017.7464
|
|
10679
Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.
Capture of mesothelioma cells with 'universal' CTC-chip.
Oncol Lett
2018
15:2635-2640
PubMed ID: 29434985
DOI: 10.3892/ol.2017.7619
|
|
10706
Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.
High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.
Oncol Lett
2018
15:3061-3067
PubMed ID: 29435038
DOI: 10.3892/ol.2017.7671
|
|
10721
Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
Oncogenesis
2018
7:11
PubMed ID: 29362358
DOI: 10.1038/s41389-017-0017-3
|
|
10768
Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.
Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.
Sci Rep
2018
8:3482
PubMed ID: 29472726
DOI: 10.1038/s41598-018-21161-y
|
|
10784
Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H.
Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy.
Int. J. Biol. Sci.
2018
14:331-340
PubMed ID: 29559850
DOI: 10.7150/ijbs.22809
|
|
10785
Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.
Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Carcinogenesis
2018
39:719-727
PubMed ID: 29546323
DOI: 10.1093/carcin/bgy044
|
|
11038
Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.
The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
Int J Mol Sci
2018
19. pii: E609
PubMed ID: 29463039
DOI: 10.3390/ijms19020609
|
|
11201
Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R.
FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
J. Exp. Clin. Cancer Res.
2018
PubMed ID: 30189871
DOI: 10.1186/s13046-018-0894-0
|
|
11307
Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Cell Stem Cell
2018
PubMed ID: 30449714
DOI: 10.1016/j.stem.2018.10.005
|
|
4141
Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C.
Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.
Oncotarget
2018
PubMed ID: 30220973
DOI: 10.18632/oncotarget.25994
|
|
4320
Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y.
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Immunol. Lett.
2018
PubMed ID: 29366663
DOI: 10.1016/j.imlet.2018.01.007
|
|
4321
Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y.
Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.
Oncotarget
2018
PubMed ID: 30680067
DOI: 10.18632/oncotarget.26494
|
|
14901
Enjoji S, Yabe R, Tsuji S, Yoshimura K, Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S, Nagano H, Oshima H, Oshima M, Vitek MP, Matsuura T, Hippo Y, Usui T, Ohama T, Sato K.
Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis
Mol Cancer Res
2018
16(3):554-563
PubMed ID: 29330298
DOI: 10.1158/1541-7786.MCR-17-0393
|
|
15838
Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Mol Cancer Ther
2018
17(8):1648-1658
PubMed ID: 29748209
DOI: 10.1158/1535-7163.MCT-17-1206
|
|
15842
Zhou P, Chen G, Gao M, Wu J.
Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC
Bioorg Med Chem
2018
26(23-24):6135-6145
PubMed ID: 30442506
DOI: 10.1016/j.bmc.2018.10.018
|
|
15843
Saito Y, Moriya S, Kazama H, Hirasawa K, Miyahara K, Kokuba H, Hino H, Kikuchi H, Takano N, Hiramoto M, Tsukahara K, Miyazawa K.
Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis
Int J Oncol
2018
1165-1177
PubMed ID: 29484439
DOI: 10.3892/ijo.2018.4282
|
|
10132
Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T.
TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas.
Oncogene
2017
36:3740-3748
PubMed ID: 28192407
DOI: 10.1038/onc.2016.524
|
|
10280
Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A.
AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Oncol. Rep.
2017
37:3261-3269
PubMed ID: 28440492
DOI: 10.3892/or.2017.5594
|
|
10317
Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y.
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.
Oncol Lett
2017
14:944-950
PubMed ID: 28693256
DOI: 10.3892/ol.2017.6188
|
|
10530
Niessen S, Dix MM, Barbas S, Potter ZE, Lu S, Brodsky O, Planken S, Behenna D, Almaden C, Gajiwala KS, Ryan K, Ferre R, Lazear MR, Hayward MM, Kath JC, Cravatt BF.
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.
Cell Chem Biol
2017
24:1388-1400.e7
PubMed ID: 28965727
DOI: 10.1016/j.chembiol.2017.08.017
|
|
13708
Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, Suzuki M, Takahashi T.
Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells
Cancer Sci
2017
108(7):1394-1404
PubMed ID: 28474808
DOI: 10.1111/cas.13271
|
|
14197
Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
J Med Chem
2017
60(7):3002-3019
PubMed ID: 28287730
DOI: 10.1021/acs.jmedchem.6b01894
|
|
14432
Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T, Noguchi M.
miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma
Cancer Sci
2017
108(3):536-542
PubMed ID: 28012229
DOI: 10.1111/cas.13148
|
|
14449
Asaka S, Yoshizawa A, Matsuda K, Yamaguchi A, Yamamoto H, Shiina T, Nakata R, Ogawa K, Zhang M, Honda T.
A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens
Oncol Rep
2017
37(2):1020-1026
PubMed ID: 27922678
DOI: 10.3892/or.2016.5287
|
|
14627
Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F.
EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'
Oncol Rep
2017
37(1):77-82
PubMed ID: 27840987
DOI: 10.3892/or.2016.5235
|
|
14680
Togo S, Katagiri N, Namba Y, Tulafu M, Nagahama K, Kadoya K, Takamochi K, Oh S, Suzuki K, Sakurai F, Mizuguchi H, Urata Y, Takahashi K.
Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients
Oncotarget
2017
8(21):34884-34895
PubMed ID: 28432274
DOI: 10.18632/oncotarget.16818
|
|
14945
Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H.
Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.
J Proteome Res
2017
16:4495-4505
PubMed ID: 28949141
DOI: 10.1021/acs.jproteome.7b00484
|
|
15850
Inoue Y, Shiihara J, Miyazawa H, Ohta H, Higo M, Nagai Y, Kobayashi K, Saijo Y, Tsuchida M, Nakayama M, Hagiwara K.
A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer
PLoS One
2017
12(4):e0176525
PubMed ID: 28448556
DOI: 10.1371/journal.pone.0176525
|
|
7069
Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Nature
2016
534:402-6
PubMed ID: 27281199
DOI: 10.1038/nature18294
|
|
9511
Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T.
ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.
Nat Commun
2016
7:10060
PubMed ID: 26725982
DOI: 10.1038/ncomms10060
|
|
9598
Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y.
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Int. J. Oncol.
2016
48:1825-36
PubMed ID: 26984042
DOI: 10.3892/ijo.2016.3419
|
|
9731
Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.
Establishment of anti-mesothelioma monoclonal antibodies.
BMC Res Notes
2016
9:324
PubMed ID: 27342200
DOI: 10.1186/s13104-016-2128-x
|
|
9884
Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C.
Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
Anticancer Res.
2016
36:6083-6092
PubMed ID: 27793936
DOI: 10.21873/anticanres.11198
|
|
10010
Koh V, Kwan HY, Tan WL, Mah TL, Yong WP.
Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.
BMC Genomics
2016
17:1029
PubMed ID: 28155658
DOI: 10.1186/s12864-016-3322-x
|
|
12883
Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki M, Takahashi T.
Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma
Cancer Sci
2016
107(2):155–161
PubMed ID: 26661061
DOI: 10.1111/cas.12858
|
|
13967
Lee Y, Choi YR, Kim KY, Shin DH.
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
Oncotarget
2016
7(28):43315-43323
PubMed ID: 27270313
DOI: 10.18632/oncotarget.9703
|
|
14033
Iyama S, Ono M, Kawai-Nakahara H, Husni RE, Dai T, Shiozawa T, Sakata A, Kohrogi H, Noguchi M.
Drebrin: A new oncofetal biomarker associated with prognosis of lung adenocarcinoma
Lung Cancer
2016
102:74-81
PubMed ID: 27987592
DOI: 10.1016/j.lungcan.2016.10.013
|
|
14179
Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
J Med Chem
2016
59(5):2005-24
PubMed ID: 26756222
DOI: 10.1021/acs.jmedchem.5b01633
|
|
7103
Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO.
Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry.
Int J Cell Biol
2015
2015:798936
PubMed ID: 26689952
DOI: 10.1155/2015/798936
|
|
7346
Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH.
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
Proc. Natl. Acad. Sci. U.S.A.
2015
112:6955-60
PubMed ID: 25971727
DOI: 10.1073/pnas.1507329112
|
|
7402
Sugita S, Ito K, Yamashiro Y, Moriya S, Che XF, Yokoyama T, Hiramoto M, Miyazawa K.
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Biochem. Biophys. Res. Commun.
2015
461:28-34
PubMed ID: 25858318
DOI: 10.1016/j.bbrc.2015.03.162
|
|
7498
Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E.
A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
Int. J. Oncol.
2015
46:1473-80
PubMed ID: 25651992
DOI: 10.3892/ijo.2015.2875
|
|
7523
Elza C. de Bruin, Ming Jiang, Michael Howell, Julian Downward
Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines.
Bio-protocol
2015
5:e1474
DOI: 10.21769/BioProtoc.1474
|
|
15025
Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y.
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment
Genome Biol
2015
16(1):66
PubMed ID: 25887790
DOI: 10.1186/s13059-015-0636-y
|
|
15223
Takahashi A, Ishii G, Ner
Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth
Oncotarget
2015
6(11):9531-41
PubMed ID: 25909164
DOI: 10.18632/oncotarget.3371
|
|
15458
Izumi H, Touge H, Igishi T, Makino H, Nishii-Ito S, Takata M, Nakazaki H, Ueda Y, Matsumoto S, Kodani M, Kurai J, Takeda K, Sakamoto T, Yanai M, Tanaka N, Nirodi CS, Shimizu E.
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies
Int J Oncol
2015
46(3):989-98
PubMed ID: 25573239
DOI: 10.3892/ijo.2015.2815
|
|
15825
Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
Cancer Sci
2014
105(10):1236-44
PubMed ID: 25154680
DOI: 10.1111/cas.12503
|
|
15832
Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, Miura S, Watanabe S, Yoshizawa H, Narita I.
DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations
PLoS One
2014
9(10):e111019
PubMed ID: 25343452
DOI: 10.1371/journal.pone.0111019
|
|
16301
Xue R, Han N, Sakurai H, Saiki I, Ye C, Yin J.
Cytotoxic cardiac glycosides from the roots of Streptocaulon juventas
Planta Med
2013
79(2):157-62
PubMed ID: 23225367
DOI: 10.1055/s-0032-1328021
|
|
15834
Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity
Cancer Biol Ther
2012
13(6):369-78.
PubMed ID: 22313637
DOI: 10.4161/cbt.19238
|
|
15715
Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H.
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma
PLoS One
2011
6(9):e25301
PubMed ID: 21966491
DOI: 10.1371/journal.pone.0025301
|
|
15844
Hotta K, Tabata M, Kiura K, Kozuki T, Hisamoto A, Katayama H, Takigawa N, Fujimoto N, Fujiwara K, Ueoka H, Tanimoto M.
Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation
Oncol Rep
2007
17(2):313-7
PubMed ID: 17203166
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
